Ingredient or product comparison
GHK-Cu Studied Osteoarthritis: Comparison of Research Models
In Vitro Chondrocyte Culture IL-1β-stimulated human chondrocytes treated with 5–10 µM GHK-Cu for 24–72 hours 40–60% reduction in IL-6, TNF-α, MMP-1, MMP-3; 35% increase in collagen type II synthesis No mechanical loading, no synovial environment, short timefra
This source-based comparison does not add ratings or recommend a winner.
- In Vitro Chondrocyte Culture
- IL-1β-stimulated human chondrocytes treated with 5–10 µM GHK-Cu for 24–72 hours
- 40–60% reduction in IL-6, TNF-α, MMP-1, MMP-3; 35% increase in collagen type II synthesis
- No mechanical loading, no synovial environment, short timeframe. Doesn't replicate joint complexity
- Establishes mechanism but limited predictive value for in vivo outcomes
- Rat MIA Model
- Intra-articular GHK-Cu injection twice weekly for 4 weeks in chemically-induced osteoarthritis
- 47% reduction in cartilage lesion area, reduced chondrocyte apoptosis, improved proteoglycan retention
- Acute chemical injury model doesn't replicate gradual mechanical wear of human osteoarthritis
- Demonstrates structural protection but mechanism may differ from age-related disease
- Rabbit ACLT Model
- GHK-Cu hydrogel implant after surgical joint destabilization, assessed at 12 weeks
- Higher Mankin scores (better cartilage integrity), reduced synovial inflammation
- Surgical trauma model. More relevant to post-traumatic OA than primary osteoarthritis
- Most clinically relevant preclinical model; extended delivery addresses half-life issue
- Human Pilot Trial
- Intra-articular injection weekly for 8 weeks in mild-to-moderate knee OA (n=22)
- 38% WOMAC pain reduction vs 12% placebo; no MRI-detectable cartilage change
- Small sample, short duration, no structural endpoint achieved. Underpowered for efficacy
- Proof-of-concept for safety and symptom relief; structural claims require longer trials